The medicine's status
A drug history, a pharmacy licence and a finished medicine are different things. Check which one a care offer is talking about.
US status
Sermorelin (Geref) had its drug approvals withdrawn from June 18, 2009, after the maker ended sales.
Geref's withdrawal from sale was not for safety or effectiveness reasons. That was the March 2013 finding of the Food and Drug Administration (FDA), the agency overseeing US drugs.
That was a finding about the old product's withdrawal, not an endorsement of medicine offered today. As of September 28, 2026, no FDA-approved sermorelin product is marketed in the US.
Making or mixing medicine to fill an order is called compounding. A licensed pharmacist or doctor, or a facility registered with FDA, can do this. It is different from a ready-made product supplied by a drug company.
The full ingredient name in the old Geref records is sermorelin acetate. Acetate tells you which form of sermorelin was used. Under FDA rules, other forms count as different ingredients.
Federal rules let a pharmacy use an ingredient from an approved drug, even when the old drug is no longer sold. On this reading, a pharmacy holding a state licence may prepare sermorelin acetate when a valid prescription names the patient, as of September 28, 2026. The ingredient's maker must be registered with FDA, and the ingredient must have a report giving the quality-test results. Any official ingredient standard that applies must be met. The pharmacy must not regularly copy a drug that is currently sold. Ask how the pharmacy meets these and any other rules for your prescription.
This guide applies the general ingredient rule to the old Geref records. FDA has not confirmed that reading for sermorelin by name under the rules for pharmacies making medicine for named patients, as of September 2026. State rules can add limits. Ask the pharmacy and your state board of pharmacy to confirm the rules for your prescription.
Will this pharmacy make the medicine for me under the federal rules called 503A?
Is it made under the different federal rules called 503B by an FDA-registered facility that makes groups of medicines together?
As of September 2026, meeting the compounding rules does not give the finished medicine FDA approval.
For larger facilities, sermorelin acetate is still under FDA review as of September 2026. It is not on their final list of allowed ingredients. FDA says it does not plan to enforce the rules about which ingredients a facility may use, if the facility meets its temporary policy's conditions. That means holding off on applying those rules in those cases. It is not drug approval. Ask the facility to show the policy and explain how your medicine meets its conditions.
A product gains no FDA approval from registration with FDA, as of September 2026. Neither does a National Drug Code (NDC), a number listed in FDA's drug directory. If an offer shows an NDC number, it is a listing, not proof of approval.
Ask the service to put in writing whether the medicine is FDA-approved or made to order by a pharmacy. Ask which rules apply to making it. Check the answer against the record, rather than relying on a badge.